Microbot Medical Meeting with Key Opinion Leaders, Hospital Administrators, and Potential Strategic and Commercial Partners at the Society of Interventional Radiologist Annual Meeting Continues to Raise Awareness of the

Medical Meeting with Key Opinion Leaders, Hospital Administrators, and Potential Strategic and Commercial Partners at the Society of

Interventional Radiologist Annual Meeting

to Raise Awareness of the LIBERTY Robotic System Ahead of Commercialization Plans

Mass., February 28, 2023 - Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic System, the first

single-use endovascular robotic system, announced that Harel Gadot, Chairman, CEO and President, Dr. Eyal Morag, Chief Medical Officer,

and other leaders from the business team, will be attending the upcoming Society of Interventional Radiologist (SIR) annual meeting.

The Company is meeting with potential strategic and commercial partners as well as leading interventional radiologists, looking to further

expand its network of Key Opinion Leaders while also sharing the progress of the LIBERTY Robotic System as it gets closer to commercialization.

value these opportunities to interact and engage with our target audience and it's important that we leverage their feedback into

our future plans for the LIBERTY Robotic System," commented Mr. Gadot. "As we get closer to the commercialization of the

LIBERTY Robotic System, our objective is to ensure a positive user experience, so the level of care delivered to patients is superior

to the current standard of care."

SIR annual meeting is being held from March 4th - 9th in Phoenix, Arizona, and is designed to meet the educational

needs of practicing Physicians, Interventional Radiologists (IR), IRs in-training, diagnostic radiologists, and other physicians with

a special interest in IR. It is the premiere venue offering IR education designed specifically for clinical associates. The meeting also

offers an interactive introduction to interventional radiology for medical students who may be considering the specialty as their focus.

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms

provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for

patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available

at http://www.microbotmedical.com.

Statements to future financial and/or operating

results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries,

along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements

that are not historical fact (including, but not limited to statements that contain words such as "will," "believes,"

"plans," "anticipates," "expects" and "estimates") should also be considered to be forward-looking

statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent

in the development and/or commercialization of potential products, including LIBERTY and the One & Done technologies, the

outcome of its studies to evaluate LIBERTY, the One & Done technologies and other existing and future technologies, any failure

or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely

affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals,

uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property

rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot

Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web

site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required